Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in British Columbia

Clinical and Vaccine Immunology

Volumn 16, Issue 12, 2009, Pages 1840-1843

  Krajden, Mel ^a,b   Karunakaran, Karuna ^b   So, Stacy ^c   Palefsky, Joel M ^d   Sharma, Rachna ^d   Cook, Darrel ^a   Yu, Amanda ^a   Chow, Ron ^c   Dobson, Simon ^b,e   Ogilvie, Gina S ^a,b   Petric, Martin ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PROVINCIAL HEALTH SERVICES AUTHORITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

AGE DISTRIBUTION; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANADA; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PRENATAL PERIOD; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRITISH COLUMBIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 73449129718     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00238-09     Document Type: Article

References (17)

1. Buck, C. B., D. V. Pastrana, D. R. Lowy, and J. T. Schiller. 2005. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119:445-462.
2. Carter, J. J., L. A. Koutsky, J. P. Hughes, S. K. Lee, J. Kuypers, N. Kiviat, and D. A. Galloway. 2000. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181:1911-1919.
3. Dessy, F. J., S. L. Giannini, C. A. Bougelet, T. J. Kemp, M.-P. M. David, S. M. Poncelet, L. A. Pinto, and M. A. Wettendorff. 2008. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the ASO4-adjuvanted HPV-16/18 cervical cancer vaccine. Hum. Vaccin. 4:425-434.
4. Ferguson, M., A. Heath, S. Johnes, S. Pagliusi, J. Dillner, et al. 2006. Results of the first W. H. O. international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int. J. Cancer 118:1508-1514.
5. Ferguson, M., D. E. Wilkinson, and T. Zhou. 2009. W. H. O. meeting on the standardization of HPV assays and the role of the W. H. O. HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 27:337-347.
6. Markowitz, L. E., M. Sternberg, E. F. Dunne, G. McQuillan, and E. R. Unger. 2009. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J. Infect. Dis. 200:1059-1067.
7. Michael, K. M., T. Waterboer, P. Sehr, A. Rother, U. Reidel, H. Boeing, I. G. Bravo, J. Schlehofer, B. C. Gartner, and M. Pawlita. 2008. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog. 4:e1000091.
8. Newell, A., J. M. L. Brotherton, H. E. Quinn, J. Backhouse, P. B. McIntyre, L. Gilbert, M. T. Esser, J. Erick, J. Bryan, N. Formica, and R. MacIntyre. 2007. Population prevalence of exposure to human papillomavirus types 6, 11, 16, and 18 in men, women and children in Australia, abstr. 4B-07. 24th Int. Papillomavirus Conf. Clin. Workshop, Beijing, China.
9. Newell, A. T., J. M. L. Brotherton, H. E. Quinn, P. B. McIntyre, J. Backhouse, L. Gilbert, M. T. Esser, J. Erick, J. Bryan, N. Formica, and C. R. MacIntyre. 2008. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin. Infect. Dis. 46:1647-1655.
10. Opalka, D., C. E. Lachman, S. A. MacMullen, K. U. Jansen, J. F. Smith, N. Chirmule, and M. T. Esser. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin. Diagn. Lab. Immunol. 10:108-115.
11. Roberts, J. N., C. B. Buck, C. D. Thompson, R. Kines, M. Bernardo, P. L. Choyke, D. R. Lowy, and J. T. Schiller. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13:857-861.
12. Ryding, J., K. M. French, P. Naucler, R. V. Barnabas, G. P. Garnett, and J. Dillner. 2008. Seroepidemiology as basis for design of a human papillomavirus vaccination program. Vaccine 26:5263-5268.
13. Schiller, John, T., and Douglas R. Lowy. 2009. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J. Infect. Dis. 200: 166-171.
14. Steele, J., S. Collins, K. Wen, G. Ryan, C. Constandinou-Williams, and C. B. J. Woodman. 2008. Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay. Clin. Vaccine Immunol. 15:1387-1390.
15. Syrjanen, S., T. Waterboer, M. Sarkola, K. Michael, M. Rintala, K. Syrjanen, S. Grenman, and M. Pawlita. 2009. Dynamics of human papillomavirus (HPV) serology in women followed-up for 36 months after pregnancy. J. Gen. Virol. 90:1515-1526.
16. Thompson, D. L., J. J. M. Douglas, M. Foster, M. E. Hagensee, C. DiGuiseppi, A. E. Baron, J. E. Cameron, T. C. Spencer, J. Zenilman, C. K. Malotte, G. Bolan, M. L. Kamb, and T. A. Peterman. 2004. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J. Infect. Dis. 190: 1563-1574.
17. Wang, S. S., M. Schiffman, T. S. Shields, R. Herrero, A. Hildesheim, M. C. Bratti, M. E. Sherman, A. C. Rodriguez, P. E. Castle, J. Morales, M. Alfaro, T. Wright, S. Chen, B. Clayman, R. D. Burk, and R. P. Viscidi. 2003. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10,000 women in Costa Rica. Br. J. Cancer 89:1248-1254.